CompletedPhase 3NCT00635765

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Studying Acromegaly

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ambrilia Biopharma, Inc.
Principal Investigator
Raphael Naudin, M.D., M.D
Ambrilia Biopharma, Inc.
Intervention
C2L-OCT-01 PR 30 mg(drug)
Enrollment
63 enrolled
Eligibility
18-65 years · All sexes
Timeline
20072009

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00635765 on ClinicalTrials.gov

Other trials for Acromegaly

Additional recruiting or active studies for the same condition.

See all trials for Acromegaly

← Back to all trials